Prognostic Factors in Breast Cancer
Patrick L. Fitzgibbons(Good Samaritan Hospital), Stuart J. Schnitt(Brigham and Women's Hospital), Stephen B. Edge(American Society of Clinical Oncology), Allen S. Lichter(Good Samaritan Hospital), Jean F. Simpson(Good Samaritan Hospital), Donald L. Weaver(University of Vermont), Daniel F. Hayes(University of Michigan–Ann Arbor), Gary M. Clark(Dana-Farber Brigham Cancer Center), David L. Page(Duke University), Stephen G. Ruby(Good Samaritan Hospital), Frances P. O’Malley(Lunenfeld-Tanenbaum Research Institute), D. Craig Allred(The University of Texas Health Science Center at San Antonio), James L. Connolly(Good Samaritan Hospital), Ann D. Thor(University of Colorado Anschutz Medical Campus)
Cited by 1,070
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Risk Factors for Breast Cancer in Women with Proliferative Breast Disease
|New England Journal of Medicine|1985|1.9k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Molecular characterization of the tumor microenvironment in breast cancer
|Cancer Cell|2004|1.3k